Akero Therapeutics, Inc. (AKRO)
After hours:
| Previous close | 22.11 |
| Open | 22.18 |
| Bid | 21.99 x 100 |
| Ask | 22.06 x 100 |
| Day's range | 21.54 - 22.25 |
| 52-week range | 11.25 - 58.38 |
| Volume | |
| Avg. volume | 1,328,647 |
| Market cap | 1.523B |
| Beta (5Y monthly) | -0.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.89 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.38 |
GlobeNewswireAkero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable pers
Insider MonkeyBillionaire Steve Cohen and Insiders Are Buying These 10 Stocks
In this article, we will take a detailed look at the Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Steve Cohen and Insiders Are Buying These 5 Stocks. Investors are holding their breath ahead of the key Fed decision about interest rates. While analysts expect the […]
ZacksMadrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
